GoodRx (GDRX) Set to Release Quarterly Earnings on Tuesday

GoodRx (NASDAQ:GDRX) is expected to post its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect the company to announce earnings of $0.0777 per share and revenue of $202.07 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:00 AM ET.

GoodRx (NASDAQ:GDRX) last released its earnings results on Wednesday, August 5th. The company reported $0.08 EPS for the quarter, hitting analysts’ consensus estimates of $0.08. GoodRx had a net margin of 2.07% and a return on equity of 7.22%. The business had revenue of $200.41 million for the quarter, compared to the consensus estimate of $193.23 million. During the same period in the previous year, the firm earned $0.09 EPS. The business’s revenue for the quarter was down 1.3% on a year-over-year basis. On average, analysts expect GoodRx to post $0.16 EPS for the current fiscal year and $0.20 EPS for the next fiscal year.

GoodRx Stock Up 0.6%

GDRX stock opened at $3.56 on Tuesday. The firm has a market cap of $1.22 billion, a PE ratio of 89.02, a P/E/G ratio of 1.76 and a beta of 1.69. GoodRx has a 12 month low of $1.77 and a 12 month high of $3.99. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.38 and a quick ratio of 1.38. The firm has a 50 day simple moving average of $3.44 and a 200 day simple moving average of $2.81.

Insider Buying and Selling

In other GoodRx news, major shareholder Francisco Partners Iv, L.P. sold 1,296,177 shares of the firm’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $3.50, for a total value of $4,536,619.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 2,760,995 shares of company stock worth $9,673,207 over the last ninety days. 5.87% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

GDRX has been the topic of several research reports. TD Cowen upped their price target on GoodRx from $4.00 to $5.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. Leerink Partners set a $5.00 price objective on GoodRx in a research note on Thursday, August 6th. Wall Street Zen raised GoodRx from a “hold” rating to a “buy” rating in a research note on Saturday, August 15th. Weiss Ratings upgraded GoodRx from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, August 7th. Finally, UBS Group boosted their target price on GoodRx from $2.50 to $3.75 and gave the stock a “neutral” rating in a research report on Thursday, August 13th. Four equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $4.23.

About GoodRx

GoodRx Holdings, Inc operates a digital healthcare platform that helps consumers find and access lower prices for prescription medications. Through its website and mobile applications, GoodRx allows users to compare prices at participating pharmacies, obtain prescription discount coupons and identify potential savings on commonly prescribed drugs. The company’s services are generally available at pharmacies across the United States.

GoodRx also offers GoodRx Gold, a membership program that provides additional discounts on eligible prescriptions, as well as healthcare-related content and tools designed to help consumers understand medications and treatment options.